Medicine

Yasuyuki Takahashi, K. Naganuma, Yuka Tanaka, N. Sakata, Taisuke Kawada, Masahiro Kizaki, S. Momose, M. Higashi, T. Tabayashi

2026.2.1Leukemia Research Reports

DOI: 10.1016/j.lrr.2026.100573

tlooto Summary

This case underscores the utility of PET/CT in detecting occult systemic disease and defines a unique, indolent clinical variant of muscular MALT lymphoma.

Abstract

We report a rare phenotype of Stage IV extranodal marginal zone lymphoma (MALT lymphoma) manifesting as diffuse, asymptomatic skeletal muscle and bone marrow infiltration in a 60-year-old female. Despite a high tumor burden and intense ¹⁸F-FDG avidity (SUVmax 8.8), muscle enzymes remained normal, indicating a non-destructive "silent infiltrator" growth pattern. The diagnosis was confirmed via biopsy (CD20+, CD5-, CyclinD1-) and negative MYD88 L265P mutation status, excluding lymphoplasmacytic lymphoma. The patient achieved a Complete Metabolic Response following Bendamustine-Rituximab therapy. This case underscores the utility of PET/CT in detecting occult systemic disease and defines a unique, indolent clinical variant of muscular MALT lymphoma.

Citation format

TAKAHASHI, Yasuyuki, et al. Systemic, asymptomatic skeletal muscle infiltration by MALT lymphoma: Defining a 'silent infiltrator' phenotype with 18F-FDG PET/CT. Leukemia Research Reports, 2026, 25: 100573.